Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

U.S. government launches CP-RND, a public-private partnership for rare neurodegenerative diseases

By Brian Buntz | September 14, 2022

CP-RNDThe FDA and NIH have debuted the Critical Path for Rare Neurodegenerative Diseases (CP-RND), a public-private partnership focused on developing new therapies for amyotrophic lateral sclerosis (ALS) and rare neurodegenerative diseases.

One of the goals of the CP-RND is to foster innovation in drug discovery and development as well as clinical testing. In addition, CP-RND will aim to develop a therapy that halts the progression of ALS.

In a similar vein, FDA launched its Action Plan for Rare Neurodegenerative Diseases in June, including amyotrophic lateral sclerosis (ALS).

FDA and NIH have chosen Tucson, Arizona-based Critical Path Institute (C-Path) to help guide the CP-RND initiative.

Founded in 2005 as a public-private partnership, C-Path is an independent, nonprofit organization.

Earlier this year, C-Path established Amsterdam as the head of its European operations.

In its work on the CP-RND project, C-Path will gather experts in rare neurodegenerative diseases from patient communities, advocacy organizations and the private sector.

“The partnership we are announcing today will leverage the shared expertise of all participants to create a path towards new breakthroughs in treating these diseases,” said FDA Chief Medical Officer Dr. Hilary Marston. “We look forward to working with NIH, C-Path and other public and private partners to carry out this important effort.”

C-Path will also use an FDA-funded project known as the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP). The RDCA-DAP infrastructure offers a central, standardized infrastructure for drug discovery and development to foster rare disease characterization.

The CP-RND initiative and RDCA-DAP platform will enable the integration of various patient data sources spanning various rare diseases.

Approximately 5,000 people in the U.S. receive an ALS diagnosis each year.

An FDA advisory panel recently recommended that the agency approve the ALS drug candidate AMX0035, which won approval in Canada this summer.

Other companies developing ALS drugs include the privately-held biotech QurAlis with its first-in-class molecule QRL-201 and Irvine, California-based Eledon Pharmaceuticals.


Filed Under: Neurological Disease
Tagged With: ALS, amyotrophic lateral sclerosis, CP-RND, FDA, NIH
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

FDA expands Vizamyl label to include quantification and therapy monitoring, creating new competitive edge
AbbVie announces head-to-head results challenging migraine treatment status quo
Human study tracks brain’s glymphatic flow in real time, opening Alzheimer’s drug avenues
An 8-year-old patient with gangliosidosis demonstrates improved mobility, walking unassisted on a soccer field after treatment with N-acetyl-L-leucine. (Still from video footage; parental consent obtained for use).
Modified amino acid approved for Niemann–Pick shows promise in early Parkinson’s research
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE